Satashia Satashia

Dr. Satashia Satashia

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2023 in CHEST Critical Care
Verified
Journal Article
Open access
SIShahin Isha
Shahin Isha
SSSatashia Satashia
Satashia Satashia
LRLekhya Raavi
Lekhya Raavi
SJSadhana Jonna
Sadhana Jonna
AJAnna Jenkins
Anna Jenkins
ARArchana Roy
Archana Roy

14 July 2024 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
SIShahin Isha
Shahin Isha
Prasanth BalasubramanianPrasanth Balasubramanian
Prasanth Balasubramanian
LRLekhya Raavi
Lekhya Raavi
AHAbby Hanson
Abby Hanson
AJAnna Jenkins
Anna Jenkins
DSDevang K. Sanghavi
Devang K. Sanghavi

11 January 2023 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
PJPatrick W. Johnson
Patrick W. Johnson
KKKatie L Kunze
Katie L Kunze
JSJonathon W. Senefeld
Jonathon W. Senefeld
JSJorge E. Sinclair
Jorge E. Sinclair
SIShahin Isha
Shahin Isha
LSLeigh L. Speicher
Leigh L. Speicher
To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently better in identifying the need for monoclonal antibody infusion throughout each "wave" of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during the coronavirus disease 2019 (COVID-19) pandemic and that the infusion of contemporary monoclonal antibody treatments is associated with a lower risk of hospitalization. In this retrospective cohort study, we evaluated the efficacy of monoclonal antibody treatment compared with that of no monoclonal antibody treatment in symptomatic adults who tested positive for SARS-CoV-2 regardless of their risk factors for disease progression or vaccination status during different periods of SARS-CoV-2 variant predominance. The primary outcome was hospitalization within 28 days after COVID-19 diagnosis. The study was conducted on patients with a diagnosis of COVID-19 from November 19, 2020, through May 12, 2022. Of the included 118,936 eligible patients, hospitalization within 28 days of COVID-19 diagnosis occurred in 2.52% (456/18,090) of patients who received monoclonal antibody treatment and 6.98% (7,037/100,846) of patients who did not. Treatment with monoclonal antibody therapies was associated with a lower risk of hospitalization when using stratified data analytics, propensity scoring, and regression and machine learning models with and without adjustments for putative confounding variables, such as advanced age and coexisting medical conditions (eg, relative risk, 0.15; 95% CI, 0.14-0.17). Among patients with mild to moderate COVID-19, including those who have been vaccinated, monoclonal antibody treatment was associated with a lower risk of hospital admission during each wave of the COVID-19 pandemic.

22 May 2024 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
OROlivia Rossnan
Olivia Rossnan
AHAbby Hanson
Abby Hanson
ASAaron Spaulding
Aaron Spaulding
SSSatashia Satashia
Satashia Satashia
SBShivang Bhakta
Shivang Bhakta
DSDevang Sanghavi
Devang Sanghavi

16 February 2023 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
OROlivia Rossnan
Olivia Rossnan
AHAbby Hanson
Abby Hanson
ASAaron Spaulding
Aaron Spaulding
SSSatashia Satashia
Satashia Satashia
SBShivang Bhakta
Shivang Bhakta
DSDevang Sanghavi
Devang Sanghavi

1 May 2023
Verified
Conference Paper
Closed access
SIShahin Isha
Shahin Isha
SSSatashia Satashia
Satashia Satashia
SYS.N.S. Yarrarapu
S.N.S. Yarrarapu
AJA. Jenkins
A. Jenkins
AHA.J. Hanson
A.J. Hanson
DSD.K. Sanghavi
D.K. Sanghavi